JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, a novel AHI-1-BCR-ABL-JAK2 interaction complex has recently been identified in CML cells, mediating these effects and playing a key role in mediation of tyrosine kinase inhibitor (TKI) response/resistance of primary CML stem/progenitor cells.